Literature DB >> 8318634

Cancer patients who refuse treatment.

S A Huchcroft1, T Snodgrass.   

Abstract

The value of cancer treatment was assessed using a 'natural experiment' where patients who refused treatment served as no-treatment controls in a situation where withholding treatment to form a control group is unethical. Each cancer patient who refused treatment in Alberta, Canada between 1975 and 1988 was compared with five subjects who accepted treatment, matched on cancer site, age, number of cancers, and time period. Variables associated with treatment-refusal were included in Cox's proportional hazards model of survival, with death from cancer as the endpoint and deaths from other causes as censored observations. Treatment was refused at a rate of 7.5 per 1,000. One-third of patients who refused treatment had lung cancer and most had unstaged disease. Treatment refusal was associated with a difference in median survival of approximately nine months. Site-specific analyses showed a range of effects. Case fatality among the treated patients fell by approximately 10 percent during the 14-year study period. Even in advanced disease, treatment can result in improved survival. However, the results of this study must be interpreted with caution and cannot be generalized to all cancer patients.

Entities:  

Keywords:  Professional Patient Relationship

Mesh:

Year:  1993        PMID: 8318634     DOI: 10.1007/bf00051311

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  10 in total

1.  What value is given to quality of life assessment by health professionals considering response to palliative chemotherapy for advanced cancer?

Authors:  I R Gough; L I Dalgleish
Journal:  Cancer       Date:  1991-07-01       Impact factor: 6.860

2.  When is a cancer treatment worthwhile?

Authors:  I F Tannock; M Boyer
Journal:  N Engl J Med       Date:  1990-10-04       Impact factor: 91.245

3.  Estimation of sample sizes in case-control studies with multiple controls per case: dichotomous data.

Authors:  K J Lui
Journal:  Am J Epidemiol       Date:  1988-05       Impact factor: 4.897

4.  Quality, evolution, and clinical implications of randomized, controlled trials on the treatment of lung cancer. A lost opportunity for meta-analysis.

Authors:  A Nicolucci; R Grilli; A A Alexanian; G Apolone; V Torri; A Liberati
Journal:  JAMA       Date:  1989-10-20       Impact factor: 56.272

5.  Treatment refusal in adolescents.

Authors:  D G Cohen
Journal:  Semin Oncol Nurs       Date:  1986-05       Impact factor: 2.315

6.  Choosing the number of controls in a matched case-control study, some sample size, power and efficiency considerations.

Authors:  J M Taylor
Journal:  Stat Med       Date:  1986 Jan-Feb       Impact factor: 2.373

7.  Considerations in determining matching criteria and stratum sizes for case-control studies.

Authors:  S Greenland; H Morgenstern; D C Thomas
Journal:  Int J Epidemiol       Date:  1981-12       Impact factor: 7.196

Review 8.  Forces of change in the health care system. Implications for cancer care in the 1990s.

Authors:  W H Ettinger
Journal:  Cancer       Date:  1991-03-15       Impact factor: 6.860

9.  Major amputations done with palliative intent in the treatment of local bony complications associated with advanced cancer.

Authors:  M M Malawer; R G Buch; W E Thompson; P H Sugarbaker
Journal:  J Surg Oncol       Date:  1991-06       Impact factor: 3.454

10.  Rural-urban differences in stage at diagnosis. Possible relationship to cancer screening.

Authors:  J M Liff; W H Chow; R S Greenberg
Journal:  Cancer       Date:  1991-03-01       Impact factor: 6.860

  10 in total
  10 in total

1.  Refusing treatment.

Authors:  Moshe Frenkel
Journal:  Oncologist       Date:  2013

2.  Cohorts and privacy.

Authors:  H B Newcombe
Journal:  Cancer Causes Control       Date:  1994-05       Impact factor: 2.506

3.  Factors influencing treatment selection and survival in advanced lung cancer.

Authors:  S Tabchi; E Kassouf; M Florescu; M Tehfe; N Blais
Journal:  Curr Oncol       Date:  2017-04-27       Impact factor: 3.677

4.  Outcome analysis of breast cancer patients who declined evidence-based treatment.

Authors:  Kurian Joseph; Sebastian Vrouwe; Anmmd Kamruzzaman; Ali Balbaid; David Fenton; Richard Berendt; Edward Yu; Patricia Tai
Journal:  World J Surg Oncol       Date:  2012-06-26       Impact factor: 2.754

5.  Characteristics of the Delayed or Refusal Therapy in Breast Cancer Patients: A Longitudinal Population-Based Study in Taiwan.

Authors:  Su Jing Chen; Pei-Tseng Kung; Kuang Hua Huang; Yueh-Hsin Wang; Wen-Chen Tsai
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

6.  Risk factors associated with treatment refusal in lung cancer.

Authors:  Won Na Suh; Kyoung Ae Kong; Yeji Han; Soo Jung Kim; Su Hwan Lee; Yon Ju Ryu; Jin Hwa Lee; Sung Shine Shim; Yookyung Kim; Jung Hyun Chang
Journal:  Thorac Cancer       Date:  2017-06-19       Impact factor: 3.500

7.  Factors involved in the delay of treatment initiation for cervical cancer patients: A nationwide population-based study.

Authors:  Szu-Ching Shen; Yao-Ching Hung; Pei-Tseng Kung; Wen-Hui Yang; Yueh-Hsin Wang; Wen-Chen Tsai
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

8.  Effect of time interval from diagnosis to treatment for cervical cancer on survival: A nationwide cohort study.

Authors:  Chao-Ping Chen; Pei-Tseng Kung; Yueh-Hsin Wang; Wen-Chen Tsai
Journal:  PLoS One       Date:  2019-09-04       Impact factor: 3.240

9.  Factors associated with lung cancer patients refusing treatment and their survival: a national cohort study under a universal health insurance in Taiwan.

Authors:  Hsiu-Ling Huang; Pei-Tseng Kung; Chang-Fang Chiu; Yueh-Hsin Wang; Wen-Chen Tsai
Journal:  PLoS One       Date:  2014-07-07       Impact factor: 3.240

10.  Characteristics, survival, and related factors of newly diagnosed colorectal cancer patients refusing cancer treatments under a universal health insurance program.

Authors:  Chun-Yi Liu; William Tzu-Liang Chen; Pei-Tseng Kung; Chang-Fang Chiu; Yueh-Hsin Wang; Shwn-Huey Shieh; Wen-Chen Tsai
Journal:  BMC Cancer       Date:  2014-06-17       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.